- Home
- DTST vs CVKD Comparison
DTST vs CVKD Comparison
Compare DTST & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTST
- CVKD
- Stock Information
- Founded
- DTST 2001
- CVKD 2022
- Country
- DTST United States
- CVKD United States
- Employees
- DTST N/A
- CVKD N/A
- Industry
- DTST EDP Services
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- DTST Technology
- CVKD Health Care
- Exchange
- DTST Nasdaq
- CVKD Nasdaq
- Market Cap
- DTST 32.6M
- CVKD 27.0M
- IPO Year
- DTST N/A
- CVKD 2023
- Fundamental
- Price
- DTST $4.16
- CVKD $13.67
- Analyst Decision
- DTST Hold
- CVKD Strong Buy
- Analyst Count
- DTST 1
- CVKD 1
- Target Price
- DTST N/A
- CVKD $32.00
- AVG Volume (30 Days)
- DTST 59.1K
- CVKD 25.7K
- Earning Date
- DTST 11-14-2025
- CVKD 11-07-2025
- Dividend Yield
- DTST N/A
- CVKD N/A
- EPS Growth
- DTST N/A
- CVKD N/A
- EPS
- DTST N/A
- CVKD N/A
- Revenue
- DTST $25,455,742.00
- CVKD N/A
- Revenue This Year
- DTST N/A
- CVKD N/A
- Revenue Next Year
- DTST N/A
- CVKD N/A
- P/E Ratio
- DTST N/A
- CVKD N/A
- Revenue Growth
- DTST 0.53
- CVKD N/A
- 52 Week Low
- DTST $2.93
- CVKD $8.74
- 52 Week High
- DTST $5.44
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- DTST 44.42
- CVKD 52.63
- Support Level
- DTST $4.10
- CVKD $12.71
- Resistance Level
- DTST $4.38
- CVKD $13.49
- Average True Range (ATR)
- DTST 0.16
- CVKD 0.77
- MACD
- DTST 0.00
- CVKD -0.07
- Stochastic Oscillator
- DTST 31.00
- CVKD 69.42
About DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.